VolitionRX Ltd reported total revenues of $985,076 for Q1 2026, a significant increase from $246,385 in Q1 2025, driven by product sales. Net loss increased to $6.7M from $5.5M year-over-year. Cash and cash equivalents reached $3.1M.
Bullish
VolitionRX Ltd's total revenues significantly increased to $985,076 for the three months ended March 31, 2026, from $246,385 in the prior year period. This growth was primarily driven by product sales of the Nu.Q Vet Cancer Test and Nu.Q Discover kits.
VolitionRX Ltd has expanded its market reach through strategic partnerships with diagnostic and liquid biopsy companies, including Werfen, Hologic, and Antech. The Nu.Q Vet Cancer Test is now available in over twenty countries, demonstrating market penetration.
VolitionRX Ltd successfully raised capital, with net cash provided by financing activities increasing to $7.6M for Q1 2026 from $3.7M in Q1 2025. Cash and cash equivalents rose to $3.1M by March 31, 2026, from $1.1M at year-end 2025.